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Prostate cancer (PCa) is the most common malignancy and the second leading cause of 
cancer death in American men. Due to the lack of accurate tests to distinguish aggressive cancer 
from indolent tumor, prostate cancer is often over-treated. Post-surgery pathology analysis 
revealed that 30% of tumors removed by radical prostatectomy are deemed clinically 
insignificant and would not have required such invasive treatment.1 Over-diagnosis and 
treatment of low-risk prostate cancer has serious and long-lasting side effect: as high as 70% of 
the patients who receive radical prostatectomy treatment will suffer a loss of sexual potency that 
cannot be remedied by drugs such as sildenafil citrate.2 We herein report a simple nanoparticle-
serum protein adsorption test that not only can distinguish prostate cancer from normal and 
benign conditions, but also is capable of predicting the aggressiveness of prostate cancer 
quantitatively. This new test could potentially deliver the long-expected and very much needed 
solution for better individualization of prostate cancer treatment.   
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The nanoparticle test we report here is based on a new bioanalytical technique, nanoparticle-
enabled dynamic light scattering assay (NanoDLSay™) that we developed earlier.3-8 This 
technique detects protein analytes by monitoring the nanoparticle size change upon specific 
binding or non-specific adsorption of target protein analytes to the AuNPs. Serum proteins tend 
to adsorb to citrate-protected AuNPs through primarily electrostatic interactions, Au-N and Au-S 
bonding to form a so-called “protein corona”.9-11 Our initial thought of using serum-AuNP 
adsorption assay for cancer biomarker discovery was based on a simple hypothesis that there 
may be some differences in the proteins adsorbed to AuNPs between cancer and non-cancer 
samples. From our previous study,8 we discovered that there is a significant difference in the 
serum-adsorbed AuNP size between mouse serum samples with and without prostate tumor. The 
average particle size of the assay solution is substantially smaller for mice carrying large tumor 
grown from orthotopically injected PC3 cells compared to healthy control mice and mice bearing 
smaller tumor grown from LnCaP cells.8 However, we did not observe the same dramatic 
difference from human serum samples with and without prostate cancer. We also could not 
explain the mechanistic origin of the observed differences.  
The biggest challenge for cancer biomarker discovery and early cancer detection is that at 
early stage, the amount of specific molecules that are released from the tumor to the blood is 
very small. In the mice model study we conducted previously,8 the relative tumor mass versus 
body weight of the PC3 and LnCaP mice was approximately 5% and 0.3%, respectively. These 
ratios would correspond to a tumor mass of 2.5 Kg and 150 g in a human patient with a body 
weight of 50 Kg. Such tumor sizes are far exceeding the tumor size from human patients with 
early stage cancer. The volume of a high grand human cancer is about 3.5-4.0 cc.12 The only 
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human setting with prostate cancer > 150 g would be the metastatic setting. It is not surprising 
that the difference found from mice models was not observed from human serum samples.  
In order to determine if the same difference observed from the mice models can be observed 
from human serum samples, we attempted to increase the amount of cancer-specific components 
by spiking the serum samples with primary tumor tissue extracts prior to the AuNP adsorption 
test. We hypothesize that when tumor-associated molecules are released to the blood, this may 
cause certain molecular changes to occur in the serum and such molecular changes are reflected 
in the AuNP-serum protein adsorption assay. By spiking a tumor tissue lysate directly to the 
blood, the concentration of tumor-associated molecules in the blood is synthetically increased, 
and as a result, molecular change of the serum similar to what occurs in in vivo may be more 
easily and clearly observed.  
We have now indeed observed the very same difference from the human serum samples as 
we observed previously from mice models: the average particle size of human serum samples 
spiked with prostate tumor tissue is significantly smaller than the serum samples spiked with 
normal prostate tissue lysates in the serum-AuNP adsorption test. In a first set of experiment, we 
tested 8 male serum samples (4 from normal donors and 4 from patients with benign prostate 
hypoplasia, BPH) spiked with 4 different prostate tissue lysates that were from normal healthy 
control, tissue with Grade 1, Grade 2, and Grade 3 prostate adenocarcinoma (Figure 1A and B, 
plot B is an expansion of plot A). All tissue lysates were prepared in the same buffer (a modified 
RIPA buffer) using exactly the same protocol and all tissue lysates have the same total protein 
concentration of 1 mg/mL. Among the 8 sets of serum samples, 7 sets exhibited a clear trend of 
decreased average particle size when the serum was spiked with prostate tumor tissue lysates. 
The average particle size is inversely related to the grade of the tumor. We tested additional sets 
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of normal and tumor tissue lysates-spiked serum samples (including data presented here, total 
approximately 100 samples made from the combination of 10 serum samples spiked with 10 
different tissue lysates), and the tests all showed the same trend of nanoparticle size reduction. 
BPH21 is the only exception observed throughout the whole study so far. Linear regression 
analyses suggest that all but BPH21 sample mixes (R squared = 0.2061, p=0.1382) had 
significant linear inverse correlations between the average particle size seen in the nanoparticle 
assay and the increasing tumor grade/staging, with goodness of fit R squared values ranging 
from 0.7406, p=0.0003 for N17 to 0.9734, p<0.0001 for BPH 23 sample sets.   
In a second set of experiment, we tested two sets of normal serum samples spiked with 
normal, BPH, and PCa tissue lysates, respectively. In the first set of samples, the two PCa tissue 
lysates are both from Grade 3 tumor: PCa1 has a Gleason Score of (4+5) and PCa2 has a Gleason 
Score of (5+4). Again, the spiking of PCa tissue lysates to the serum led to a much smaller 
average particle size of the assay solution. Between the two BPH tissue lysates, one behaved like 
the normal tissue, and another one caused the particle size decrease of the assay solution; 
however, the decrease is smaller than the PCa tissue lysates. There is also a difference between 
the two PCa tissue samples: PCa2 caused more substantial particle size decrease than PCa1, even 
though PCa1 has a Gleason score of (5+4) while PCa2 has a Gleason score of (4+5). In contrast 
to the pathological analysis, the AuNP adsorption assay we conducted here suggests that PCa2 is 
more aggressive than PCa1. We also observed a concentration-dependent effect: PCa2 tissue 
lysate was spiked into the same serum in 1:20 and 1:100 (lysate:serum, v/v) ratio, respectively. 
With an increased amount of tissue lysate spiked into the serum, the particle size decreasing 
effect caused by the tumor tissue lysate is more dramatic.  
5 
 
The second set of samples showed very similar results (Figure 1D): the BPH tissue lysate-
spiked samples showed slight nanoparticle size reduction compare to the normal samples, while 
4 out of 5 tumor tissue lysate-spiked samples showed substantial nanoparticle size reduction 
compared to the normal tissue lysates. The most aggressive tumor among the five samples, #15 
from a donor of age 47 with a Gleason score of 8, showed the largest nanoparticle size reduction. 
On the other hand, sample #11, a tumor with a Gleason score of 7, exhibited a similar behavior 
as a normal tissue sample. Even with the small number of samples tested in this study, marked 
discrepancy can already be seen between the new test results and the pathology reports.  
Based on ours and others’ studies,8,9 we suggested that the major components in the protein 
corona formed on the AuNPs are abundant serum proteins. Circulating immunoglobulin G (IgG) 
is one of the most abundant blood serum proteins, with a typical concentration in the range of 5-
15 mg/mL. IgG is known to have strong affinity towards citrate-protected AuNPs, a property that 
has been used for decades as a general method to prepare AuNP immunoprobes through a simple 
adsorption process.13 If IgG is indeed a major component in the protein corona adsorbed to the 
AuNPs, the observed difference between cancer and non-cancer samples could then have been 
due to the unique interactions between tumor-specific molecules and IgG. To test if this is the 
case, we conducted the same AuNP adsorption assay on pure human IgG solution spiked with 42 
prostate tissue lysates. Remarkably, we observed the similar particle size differences between 
tumor, benign and normal tissue-spiked IgG solution (Figure 2). Furthermore, the average 
particle size of the assay solution is inversely related to the tumor grade. The normal and the 
most aggressive Grade 3 tumor can be clearly differentiated without any overlap. Most benign 
and Grade 1 tumor tissues gave similar results as normal tissues, but with two samples 
resembling a more aggressive tumor profile. The assay results of 11 Grade 2 tumor tissues 
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extend over a wide range, reflecting exactly the ambiguous aggressiveness of the Grade 2 tumor. 
If the ‘normal range’ threshold is set as 2SD below the mean of the normal control group (red 
dotted line), the Grade 2 and 3 tumors are detected with 100% sensitivity. However, most low-
grade prostate tumors are slow-growing tumors. A more extensive clinical study on a larger data 
set needs to be conducted to establish the best cut-off value/range for treatment selection. 
According to the data obtained so far, it appears that this suitable cut-off value may appear 
somewhere in the average particle size range of 190-200 nm (blue dotted line).    
Although we do not have the full landscaping of the interactions between tumor molecules 
and serum IgG, one possible model for the assay mechanism is illustrated in Figure 3 to explain 
the observed results. IgG, either as a monomer or oligomer, causes AuNP cluster formation when 
adsorbed to the AuNPs. When mixing IgG solution or serum with tumor tissue lysates, the 
specific binding of tumor-specific molecules with IgG inhibits the crosslinking of the AuNPs, 
leading to a decreased average nanoparticle size of the assay solution. This mechanism suggests 
that serum IgG, by interacting with tumor-associated, enhanced or altered molecules, may be 
providing a natural defense line against prostate cancer spreading in the blood. If this natural 
defense system is exhausted, cancer metastasis can begin. This model, very interestingly, echoes 
well with the findings on the association between cancer and the immune system/functions.14-16  
The above model also implicates that the best serum biomarker for early detection of 
aggressive prostate cancer may be found from the complexes with serum IgG, not as individual 
molecules in the blood. If the tumor-specific molecules are interacting with circulating IgGs at a 
typical antibody-antigen binding constant of 1010 M-1, a simple calculation (assuming the serum 
IgG concentration is at an average value of 10 mg/mL) reveals that the concentration of IgG-
complexed tumor biomarkers would be 600,000 times of the free biomarker molecules in the 
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blood. This means at early stage of cancer development, almost all cancer biomarker molecules 
released from the tumor site to the blood are complexed to the serum IgGs. Current bioassays are 
set almost exclusively to detect target protein analytes in individual molecular forms, not in 
complexes. This is perhaps a key reason why no suitable serum biomarkers have been found for 
early detection of any type of cancer, despite the extensive efforts invested from the whole 
research community in the last few decades.  
In summary, we reported here a simple nanoparticle assay for quantitative assessment of the 
prostate tumor aggressiveness. The significant inverse correlation of the average nanoparticle 
size of the assay solution with tumor histological diagnostic grading suggests that the 
nanoparticle assay could potentially provide a more accurate diagnostic tool to assess the tumor 
aggressiveness than the current diagnostic practices. A large scale clinical study to validate this 
new test is fully justified. The current assay still requires the use of biopsied tissue samples. 
Currently, we are conducting further studies to identify the specific tumor molecules that are 
complexed with serum IgG. We expect sensitive serum biomarkers for early detection of 
aggressive prostate cancer using only blood samples to be discovered from these studies.    
 
METHODS 
Materials: Citrate-protected gold nanoparticle (AuNP) (15708-9) was purchased from Ted Pella 
Inc. (Redding, CA). The average diameter of the citrate AuNP is 100 nm and the concentration 
of the nanoparticle is 10 pM. Pure human IgG (ab91102) was purchased from Abcam 
(www.abcam.com). All human serum samples were purchased from Asterand Solutions 
(www.asterand.com). Tissue lysate samples were purchased from Protein Biotechnologies 
(www.proteinbiotechnologies.com). The protocol used for preparing the tissue lysates can be 
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found from the website of Protein Biotechnologies and is also summarized in the Supplementary 
Information along with the clinical data of tissue samples. All human tissue and serum samples 
used in this study are de-identified, archived specimens. University of Central Florida IRB 
committee approved the use of these commercially acquired samples with IRB exemption. 
Dynamic Light Scattering Analysis: Particle size analysis of the assay solutions was conducted 
using an automatic DLS instrument, NDS1200, from Nano Discovery Inc. (Orlando, Florida, 
www.nanodiscoveryinc.com). This system is equipped with a 12-sample holder carousel to allow 
automatic measurement of 12 samples within 5-6 minutes. The measurement error for the pure 
AuNP solution with an average diameter of 100 nm is ±2 nm.  
Sample Preparation and Assay Methods: To prepare tissue lysate-spiked serum samples or pure 
IgG solutions, 1 µL lysate at a total protein concentration of 1 mg/mL was mixed with 20 µL 
serum or IgG solution (concentration of 1 mg/mL in phosphate buffer, pH 7.4). The mixed 
solution was set at 4oC overnight for tissue lysate-spiked serum samples, and 30 minutes at room 
temperature for tissue lysate-spiked IgG samples before nanoparticle assay was conducted. To 
conduct the AuNP adsorption assay, 2 µL sample solution was mixed with 40 µL AuNP 
solution. The serum-AuNP solution was incubated for 8 min, and the IgG-AuNP was incubated 
for 3 min at room temperature before particle size was measured. All assays were conducted in 
duplicate and the error bars in each plot represent the standard error of the assay. 
Statistical Analysis Methods: Where possible, data were analyzed by one-way ANOVA for 
multiple variant analysis, and using Student t test or nonparametric Mann–Whitney U tests for 
pairwise analyses. The results of these analyses are listed with appropriate p values and statistical 
parameters (n, mean, SD and/or SEM) on the figures, in figure legends and/or in the text. The 
designation ‘ns’ is listed where statistical analysis was applied and no statistical significance 
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between the groups was obtained.  Linear regression analysis for data presented in Figure 1 was 
done with significance determined by comparing slope deviation from zero and the R squared 
value for fit on each of the assay sets presented.  
 
Note: Supplementary Information is available. 
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Figure Legends 
 
Figure 1. The AuNP adsorption assay results of serum spiked with different prostate tissue 
lysates. A and B: the assay results of 8 serum (normal healthy donor = 4; BPH = 4) spiked with 4 
prostate tissue lysates from normal, tissue with Grade 1, Grade 2, and Grade 3 prostate 
adenocarcinoma. The Gleason scores of the three tumor tissues are: 4(2+2), 5(2+3), and 9(5+4), 
respectively. A is the scatter-plot of all 32 samples and B is an expansion of A with 6 samples 
that have relatively smaller average particle sizes. Linear regression analysis of each sample set 
suggests that all but BPH21 sample mixes (R squared= 0.2061, p=0.1382) had significant linear 
inverse correlations between the average particle size seen in the nanoparticle assay and the 
increasing tumor grade/staging, with goodness of fit R squared values ranging from 0.7406, 
p=0.0003 for N17 to 0.9734, p<0.0001 for BPH 23 sample sets. C and D: two sets of assay 
results of two different serum samples spiked with tissue lysates from normal healthy donors, 
BPH patients, and PCa donors. In the first set (C), PCa2 tissue lysate was spiked to the serum at 
two different ratios: 1:20 and 1:100 (tissue lysate:serum, v/v). Statistically significant differences 
were found in the assay results between the normal controls (mean 196.1± 11.3SD) and BPH 
samples (mean 183.8 ± 6.4SD; p=0.0078, Student t test), BPH and PCa samples (mean 158.4± 
16.3SD; p=0.0051, Mann-Whitney U test), and normal and PCa samples (p<0.0001, Student t 
test). 
 
Figure 2. The AuNP adsorption assay results of pure human IgG solution spiked with different 
prostate tissue lysates. The concentration of IgG solution was 1 mg/mL in phosphate buffer (10 
mM, pH 7.4). The ‘normal range’ threshold (red dotted line) was set as 2SD below the mean of 
the normal control group analyses. 
 
Figure 3. A mechanistic model to explain the observed difference between normal and prostate 
cancer with different tumor grades in the AuNP adsorption assay.  
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